Video

Dr. Gary Schwartz on the Survival Benefit of Eribulin In Sarcoma

Author(s):

Gary Schwartz, MD

In Partnership With:

Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

Eribulin lengthened survival by eight weeks compared to dacarbazine, which is significant in sarcoma, a disease that has never had a survival benefit from a novel therapy, says Schwartz.

Median overall survival for eribulin and dacarbazine was 13.5 and 11.5 months, respectively (HR = 0.768, 95% CI 0.618—0.954; P= 0.017). Progression-free survival was 2.6 months in both arms (HR = 0.877, 95% CI 0.710–1.085; P= 0.229).

Eribulin is approved to treat metastatic breast cancer. This study represents one of the first times it has been investigated in sarcoma.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD
Related Content
Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
December 3rd 2024

Research Provides Insights Into Real-World CAR T-Cell Therapy and Bispecific Antibody Use in DLBCL

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Suzanne Lentzsch, MD, PhD
August 15th 2024

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

Ian Flinn, MD, PhD; Nicole Lamanna, MD; Jennifer R. Brown, MD, PhD; Constantine Tam, MD, MBBS
February 16th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

Sunil Iyer, MD, of Columbia University Irving Medical Center
March 28th 2024

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

Sunil Iyer, MD
March 26th 2024

Luspatercept Provides Effective First-Line Alternative to ESAs in Lower-Risk MDS